KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 17.03 CNY -1.73% Market Closed
Market Cap: 12.9B CNY
Have any thoughts about
KPC Pharmaceuticals Inc?
Write Note

Operating Margin
KPC Pharmaceuticals Inc

7.6%
Current
7%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.6%
=
Operating Profit
575.3m
/
Revenue
7.5B

Operating Margin Across Competitors

Country CN
Market Cap 12.9B CNY
Operating Margin
8%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 729.3B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.6T DKK
Operating Margin
44%
Country US
Market Cap 347.8B USD
Operating Margin
28%
Country US
Market Cap 248.3B USD
Operating Margin
34%
Country CH
Market Cap 197.2B CHF
Operating Margin
32%
Country UK
Market Cap 159B GBP
Operating Margin
21%
Country CH
Market Cap 169.7B CHF
Operating Margin
31%
Country US
Market Cap 149.4B USD
Operating Margin
22%
No Stocks Found

KPC Pharmaceuticals Inc
Glance View

Market Cap
12.9B CNY
Industry
Pharmaceuticals

KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.

Intrinsic Value
24.27 CNY
Undervaluation 30%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.6%
=
Operating Profit
575.3m
/
Revenue
7.5B
What is the Operating Margin of KPC Pharmaceuticals Inc?

Based on KPC Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 7.6%.